NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.28 0.00 (0.00 %)
(As of 02/15/2019 01:55 PM ET)
Previous Close$0.2830
Today's Range$0.28 - $0.28
52-Week Range$0.07 - $2.26
Volume2,505 shs
Average Volume9.20 million shs
Market Capitalization$69.45 million
P/E Ratio-0.27
Dividend YieldN/A
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SGYP



Sales & Book Value

Annual Sales$16.82 million
Book Value($0.02) per share


Net Income$-224,330,000.00
Net Margins-332.11%


Market Cap$69.45 million

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million. View Synergy Pharmaceuticals' Earnings History.

When is Synergy Pharmaceuticals' next earnings date?

Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Synergy Pharmaceuticals.

What price target have analysts set for SGYP?

5 brokerages have issued 12-month price objectives for Synergy Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 2,400.0% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.

What is the consensus analysts' recommendation for Synergy Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.

Has Synergy Pharmaceuticals been receiving favorable news coverage?

Press coverage about SGYP stock has trended somewhat positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future.

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 18,430,902 shares, an increase of 8.9% from the January 15th total of 16,919,869 shares. Based on an average daily volume of 13,023,997 shares, the short-interest ratio is currently 1.4 days. Currently, 7.5% of the shares of the stock are sold short. View Synergy Pharmaceuticals' Current Options Chain.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:
  • Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)
  • Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)
  • Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
  • Ms. Pamela Cebulski, Sr. VP of Marketing
  • Ms. Marianne Jackson, Sr. VP of Sales & Market Access

Who are Synergy Pharmaceuticals' major shareholders?

Synergy Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.87%), Northern Trust Corp (1.00%), Opti Capital Management LP (0.35%), Geode Capital Management LLC (0.30%), Bank of New York Mellon Corp (0.27%) and Rhumbline Advisers (0.13%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Which institutional investors are selling Synergy Pharmaceuticals stock?

SGYP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Synergy Pharmaceuticals.

Which institutional investors are buying Synergy Pharmaceuticals stock?

SGYP stock was purchased by a variety of institutional investors in the last quarter, including Opti Capital Management LP, Paloma Partners Management Co and Rhumbline Advisers. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy shares of Synergy Pharmaceuticals?

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of SGYP stock can currently be purchased for approximately $0.28.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $69.45 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

What is Synergy Pharmaceuticals' official website?

The official website for Synergy Pharmaceuticals is

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]

MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  647 (Vote Outperform)
Underperform Votes:  351 (Vote Underperform)
Total Votes:  998
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel